J Med Genet

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
[Advanced]

The most recent version of this article was published on 1 October 2008

J Med Genet. Published Online First: 29 May 2008. doi:10.1136/jmg.2008.059329
Copyright © 2008 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
jmg.2008.059329v1
45/10/622    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Kehrer-Sawatzki, H.
Right arrow Articles by Cooper, D. N
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kehrer-Sawatzki, H.
Right arrow Articles by Cooper, D. N

Review article

Mosaicism in Sporadic Neurofibromatosis Type 1: Variations on a Theme Common to Other Hereditary Cancer Syndromes?

Hildegard Kehrer-Sawatzki 1* and David N Cooper 2

1 University of Ulm, Germany
2 Institute of Medical Genetics, United Kingdom

* To whom correspondence should be addressed. E-mail: hildegard.kehrer-sawatzki{at}uni-ulm.de.

Accepted 4 May 2008


*   Abstract

Mosaicism constitutes a frequent complication of the genotype-phenotype relationship in genetic disease and is an important consideration for the estimation of transmission risk. Mosaicism has been identified in several hereditary cancer syndromes including retinoblastoma, familial adenomatous polyposis coli, von Hippel-Lindau disease and neurofibromatosis type 2. Recent data support the postulate that the frequency of mosaicism is increased in cancer predisposition syndromes characterized by high new mutation rates. Since the new mutation rate is very high in neurofibromatosis type 1 (NF1), mosaicism might reasonably be expected to be frequent among sporadic cases but this remains to be formally demonstrated. Here we summarize current knowledge of mosaicism in NF1, focussing on the types of mutations identified as well as their inferred developmental timing and representation in different cell types, and assess the potential impact of high frequency mosaicism on mutation screening in patients with apparent de novo NF1.








HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd.